Sri Lanka to administer Pfizer vaccine as the second dose for AstraZeneca first dose receivers
Currently, the World Health Organization (WHO) has confirmed that people who have taken the first dose of AstraZeneca can be given Pfizer vaccine as the second dose.
This option is considered because of the shortage of AstraZeneca doses in the world, to be administered as a second dose for Sri Lankans. Sri Lanka is in need of around 600,000 doses of AstraZeneca vaccines.
A German study reports that a combination of AstraZeneca and Biotech vaccines triggers remarkably stronger immune responses rather than jabbing both doses with the same vaccine.
The State Pharmaceutical Corporation (SPC) held talks with the Pfizer authorities yesterday and discussed how to work out logistical arrangements for the distribution of their vaccines. Sri Lanka will receive a dispatch of 300,000 doses of Pfizer vaccines in the middle of next month.
Latest Headlines in Sri Lanka
- Sri Lanka President leads discussion on strengthening airport security and combating corruption December 28, 2024
- CAA imposes new maximum retail prices for canned fish effective today December 28, 2024
- Ex-Minister Manusha’s brother arrested in Rs. 3 million job scam December 28, 2024
- Mahinda Rajapaksa’s security chief Neville and son Yoshitha summoned to CID December 28, 2024
- Salochana Gamage arrested by CIABOC in Rs. 9 million bribery case December 28, 2024
Hi Indra Akke,
Your brilliant views please?
Astra Zeneca and Pfizer were developed on different technologies. Compatibility is not established.
Pfizer, which has reportedly nil side effects, is difficult to obtain.
How can we plan to provide Pfizer as the 2nd vaccine?
State minister himself can take this ‘mix’ of vaccines and set an example to ord citizens. It will be more convincing to all !
Concerned,
He will never do that.
They protect themselves and there cohorts, pretty effectively while the gen population die due to lack of vaccines, or the Chinese vaccine or the Russian vaccine and the mix of vaccines.